Preface
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago, USA from May 31 to June 4, local time. This year, 5 LBA studies stood out and were selected for the plenary session of the ASCO Annual Meeting, which is expected to change the current clinical diagnosis and treatment practice of oncology.
LBA 1
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)
ESPOC Study: A prospective, randomized, multicenter phase III study comparing perioperative chemotherapy (FLOT regimen) with neoadjuvant chemoradiotherapy (CROSS regimen) in patients with esophageal adenocarcinoma
Written by: Jens Hoeppner 比勒费尔德大学
Whether neoadjuvant chemoradiotherapy is superior to perioperative chemotherapy is a key question in the field of early-stage esophageal cancer. In the Neo-AEGIS study, there was no significant difference in the 3-year overall survival (OS) rate, surgical outcome, or health-related quality of life between perioperative chemotherapy (mainly modified MAGIC) and neoadjuvant chemoradiotherapy (CROSS) in the treatment of esophageal/esophagogastric junction (E/GEJ) adenocarcinoma. The ESPOC study mainly compares the efficacy of perioperative FLOT chemotherapy and neoadjuvant chemoradiotherapy (CROSS), which is expected to answer the controversy over the superiority of neoadjuvant chemoradiotherapy and perioperative chemotherapy for esophageal adenocarcinoma.
LBA 2
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial
NADINA Study: Neoadjuvant Nivolumab + Ipilimumab Versus Adjuvant Nivolumab in Macroscopic Resectable Stage III Melanoma
讲者：Christian U. Blank 荷兰癌症研究所
The results of the OpACIN-neo and its extended cohort PRADO suggest that the dual immunotherapy combination of nivolumab + ipilimumab is an ideal neoadjuvant treatment for melanoma. The NADINA study, which further compared adjuvant neotherapy with adjuvant immune monotherapy, was selected by Nature Medicine as one of the most anticipated clinical trials in 2024.
LBA 3
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer
An effectiveness trial of early palliative care in patients with advanced lung cancer compared to in-person via telemedicine
讲者：Joseph A. Greer 麻省总医院
With the integrated development of medical technology and information technology, telemedicine has gradually become a hot field of research in the medical and health industry. Telemedicine has unique advantages in promoting disease management and quality of life for cancer patients. This study helps clarify the role of telemedicine in palliative care for patients with advanced lung cancer and help more patients and caregivers access palliative care.
LBA 4
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
LAURA Study: Patients with unresectable stage III epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) treated with osimertinib after concurrent chemoradiotherapy (CRT).
讲者：Suresh S. Ramalingam 埃默里大学温希普癌症研究所
The PACIFIC study has demonstrated a significant survival benefit with durvalumab consolidation therapy for stage III unresectable NSCLC followed by radical chemoradiotherapy. However, post-hoc analysis of the PACIFIC study suggested that the benefit of chemoradiotherapy followed by immunomaintenance therapy in patients with EGFR-positive stage III unresectable NSCLC was unclear. The LAURA study is designed to evaluate the efficacy and safety of stage III unresectable EGFR-positive NSCLC followed by osimertinib consolidation. The results of this study are expected to change the treatment landscape for unresectable stage III NSCLC.
LBA 5
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
ADRIATIC Study: durvalumab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC).
讲者:David R. Spigel 萨拉坎农研究所
With the advent of immunotherapy and the exploration in the field of SCLC, PD-1/PD-L1 inhibitors combined with chemotherapy have significantly improved the OS of patients with extensive-stage SCLC, but their efficacy in limited-stage SCLC still lacks high-level evidence-based medical evidence. Based on the favorable benefits of durvalumab in the CASPIAN study and the success of the PACIFIC study, the ADRIATIC study explored the safety and efficacy of durvalumab with or without tremelimumab as consolidation therapy for patients with limited-stage SCLC who are stable after cCRT therapy. It is reported that the ADRIATIC study has achieved both PFS and OS benefits, and has strongly confirmed the effectiveness of durvalumab as a consolidation therapy for patients with limited-stage SCLC with stable disease after cCRT with solid evidence-based medical evidence.
Editor: Faline
审校:Faline
Typesetting: Faline
Execution: Faline
This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.